Bank of New York Mellon Corp grew its stake in Immunomedics, Inc. (NASDAQ:IMMU) by 35.3% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 628,135 shares of the biopharmaceutical company’s stock after buying an additional 163,920 shares during the period. Bank of New York Mellon Corp owned approximately 0.57% of Immunomedics worth $5,546,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. SG Americas Securities LLC boosted its stake in shares of Immunomedics by 99.3% during the 2nd quarter. SG Americas Securities LLC now owns 20,719 shares of the biopharmaceutical company’s stock worth $183,000 after acquiring an additional 10,323 shares in the last quarter. Bank of America Corp DE raised its stake in shares of Immunomedics by 38.8% in the 1st quarter. Bank of America Corp DE now owns 33,707 shares of the biopharmaceutical company’s stock valued at $218,000 after acquiring an additional 9,426 shares in the last quarter. Trexquant Investment LP bought a new position in shares of Immunomedics in the 2nd quarter valued at approximately $256,000. First Heartland Consultants Inc. raised its stake in shares of Immunomedics by 35.3% in the 1st quarter. First Heartland Consultants Inc. now owns 49,800 shares of the biopharmaceutical company’s stock valued at $322,000 after acquiring an additional 13,000 shares in the last quarter. Finally, HighTower Advisors LLC raised its stake in shares of Immunomedics by 13.8% in the 1st quarter. HighTower Advisors LLC now owns 58,115 shares of the biopharmaceutical company’s stock valued at $375,000 after acquiring an additional 7,050 shares in the last quarter. 57.36% of the stock is owned by institutional investors.

Several equities research analysts recently weighed in on IMMU shares. Jefferies Group LLC set a $9.00 target price on Immunomedics and gave the stock a “buy” rating in a report on Saturday, June 10th. Zacks Investment Research raised Immunomedics from a “sell” rating to a “buy” rating and set a $9.50 target price for the company in a research report on Tuesday, July 11th. Cowen and Company reiterated an “outperform” rating and set a $15.00 price target on shares of Immunomedics in a report on Monday, July 24th. Finally, BidaskClub downgraded Immunomedics from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 25th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Immunomedics presently has a consensus rating of “Buy” and a consensus price target of $13.00.

Immunomedics, Inc. (IMMU) opened at 13.40 on Wednesday. The company has a 50-day moving average of $11.39 and a 200 day moving average of $8.43. Immunomedics, Inc. has a one year low of $2.02 and a one year high of $14.48. The company’s market cap is $1.49 billion.

Immunomedics (NASDAQ:IMMU) last announced its quarterly earnings data on Wednesday, August 16th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.13). The firm had revenue of $0.64 million for the quarter, compared to the consensus estimate of $0.75 million. During the same period in the previous year, the business posted ($0.17) earnings per share. Immunomedics’s revenue for the quarter was down 31.2% on a year-over-year basis. Equities research analysts predict that Immunomedics, Inc. will post ($0.53) EPS for the current year.

In related news, insider David M. Goldenberg sold 20,000 shares of Immunomedics stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $12.64, for a total transaction of $252,800.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Cynthia L. Goldenberg sold 40,000 shares of Immunomedics stock in a transaction dated Monday, August 28th. The stock was sold at an average price of $10.72, for a total value of $428,800.00. The disclosure for this sale can be found here. Insiders have sold a total of 100,000 shares of company stock worth $1,051,200 over the last 90 days. 6.60% of the stock is owned by company insiders.

WARNING: This piece was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.watchlistnews.com/bank-of-new-york-mellon-corp-has-5-55-million-holdings-in-immunomedics-inc-immu/1606684.html.

About Immunomedics

Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.

Want to see what other hedge funds are holding IMMU? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immunomedics, Inc. (NASDAQ:IMMU).

Institutional Ownership by Quarter for Immunomedics (NASDAQ:IMMU)

Receive News & Ratings for Immunomedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.